Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 4;29(4):303-312.
doi: 10.1188/25.CJON.303-312.

Blinatumomab Administration in Pediatric B-Lineage ALL: Expert Recommendations From the Children's Oncology Group

Holly R Kubaney  1 , Kathleen E Montgomery  2 , Lauren Guidry  3 , Maki Okada  4 , Katelyn Oranges  5 , Shelby Smith  6 , Megan Elizabeth Wegter  7 , Olga Militano  8 , Sumit Gupta  9 , Rachel Rau  10 , Sue Zupanec  11
Affiliations

Blinatumomab Administration in Pediatric B-Lineage ALL: Expert Recommendations From the Children's Oncology Group

Holly R Kubaney et al. Clin J Oncol Nurs. .

Abstract

Background: The addition of blinatumomab to chemotherapy is the new standard of care for most pediatric patients with B-lineage acute lymphoblastic leukemia (B-ALL), and its use has increased rapidly. Administering blinatumomab to pediatric patients is associated with a spectrum of unique challenges, resulting in variable practices across institutions.

Objectives: This article presents expert recommendations for blinatumomab administration in patients with pediatric B-ALL.

Methods: Pediatric oncology nurses, physicians, and pharmacists collated current evidence and Children's Oncology Group institutional experiences to identify considerations for planning for blinatumomab administration, initiating and managing infusions, and monitoring for adverse events.

Findings: Engaging patients, families, and clinicians promotes care transitions between inpatient and outpatient settings and minimizes complications. Ongoing institutional commitment to monitor and capture emerging trends in blinatumomab administration can inform future optimal care practices.

Keywords: B-lineage acute lymphoblastic leukemia; blinatumomab; home infusion therapy.

PubMed Disclaimer

References

    1. AmgenBLINCYTO® (blinatumomab) for injection, for intravenous use [Package insert] 2024. https://www.pi.amgen.com/-/media/Project/Amgen/Repository/pi-amgen-com/B... .
    1. Angiolillo A, Schore R, Devidas M, Lu X, Rabin KR, Zweidler-McKay PA, Hunger SP. Intensification of oral methotrexate is not superior to standard methotrexate dosing during maintenance in children with National Cancer Institute (NCI) standard-risk B acute lymphoblastic leukemia (SR B-ALL): A report from Children’s Oncology Group (COG) study AALL0932. Blood. 2017;130(Suppl 1):140.
    1. Attarbaschi A, Mann G, Zimmermann M, Bader P, Barisone E, Basso G, Rizzari C. Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: Long-term results of the international AIEOP-BFM ALL 2000 trial. Leukemia. 2020;34(6):1694–1700. doi: 10.1038/s41375-019-0670-y. - DOI - PubMed
    1. Bernhardt MB, Militano O, Honeyford L, Zupanec S. Blinatumomab use in pediatric ALL: Taking a BiTE out of preparation, administration and toxicity challenges. Journal of Oncology Pharmacy Practice. 2021;27(2):376–388. doi: 10.1177/1078155220979047. - DOI - PubMed
    1. Bhojwani D, Bansal R, Wayne AS. Managing therapy-associated neurotoxicity in children with ALL. Hematology. American Society of Hematology Education Program. 2021;2021;1:376–383. doi: 10.1182/hematology.2021000269. - DOI - PMC - PubMed

LinkOut - more resources